The latest price target for Tandem Diabetes Care (NASDAQ:TNDM) was reported by Morgan Stanley on December 2, 2024. The analyst firm set a price target for $45.00 expecting TNDM to rise to within 12 months (a possible 37.07% upside). 32 analyst firms have reported ratings in the last year.

The latest analyst rating for Tandem Diabetes Care (NASDAQ:TNDM) was provided by Morgan Stanley, and Tandem Diabetes Care upgraded their overweight rating.

The last upgrade for Tandem Diabetes Care Inc happened on December 2, 2024 when Morgan Stanley raised their price target to $45. Morgan Stanley previously had an equal-weight for Tandem Diabetes Care Inc.

The last downgrade for Tandem Diabetes Care Inc happened on August 4, 2023 when Citigroup changed their price target from $45 to $33 for Tandem Diabetes Care Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tandem Diabetes Care, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tandem Diabetes Care was filed on December 2, 2024 so you should expect the next rating to be made available sometime around December 2, 2025.

While ratings are subjective and will change, the latest Tandem Diabetes Care (TNDM) rating was a upgraded with a price target of $45.00 to $45.00. The current price Tandem Diabetes Care (TNDM) is trading at is $32.83, which is out of the analyst’s predicted range.